ArticleEvolutionary applications2018
The effects of subcurative praziquantel treatment on life-history traits and trade-offs in drug-resistant
Article in Evolutionary applications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Schistosomiasis Interventions in Africa: Assessment and Systematic Review.Journal of parasitology research · 2025Review
- Review
- Identification of antiparasitic drug targets using a multi-omics workflow in the acanthocephalan model.BMC genomics · 2022Article
- Reconciling Egg- and Antigen-Based Estimates of Schistosoma mansoni Clearance and Reinfection: A Modeling Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Assessing Potential Intermediate Host Snails of Urogenital Schistosomiasis, Human Water Contact Behavior and Water Physico-chemical Characteristics in Alwero Dam Reservoir, Ethiopia.Environmental health insights · 2022Article
- Whole-genome sequencing of Schistosoma mansoni reveals extensive diversity with limited selection despite mass drug administration.Nature communications · 2021Article
- Schistosomiasis Morbidity Hotspots: Roles of the Human Host, the Parasite and Their Interface in the Development of Severe Morbidity.Frontiers in immunology · 2021Review
- Cloning and functional complementation of ten Schistosoma mansoni phosphodiesterases expressed in the mammalian host stages.PLoS neglected tropical diseases · 2020Article
- Concomitant Immunity and Worm Senescence May Drive Schistosomiasis Epidemiological Patterns: An Eco-Evolutionary Perspective.Frontiers in immunology · 2020Review
- Schistosomiasis: Life Cycle, Diagnosis, and Control.Current therapeutic research, clinical and experimental · 2019Review
- Evolutionary perspectives on human infectious diseases: Challenges, advances, and promises.Evolutionary applications · 2018Article
- The effects of subcurative praziquantel treatment on life-history traits and trade-offs in drug-resistantEvolutionary applications · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Natural selection acts on all organisms, including parasites, to maximize reproductive fitness. Drug resistance traits are often associated with life-history costs in the absence of treatment. Schistosomiasis control programmes rely on mass drug administration to reduce human morbidity and mortality. Although hotspots of reduced drug efficacy have been reported, resistance is not widespread. Using Bayesian state-space models (SSMs) fitted to data from an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.